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Summary
Prior to the implementation of predictive-testing pro-
grams for Huntington disease (HD), significant concern
was raised concerning the likelihood of catastrophic
events (CEs), particularly in those persons receiving an
increased-risk result. We have investigated the frequency
of CEs—that is, suicide, suicide attempt, and psychiatric
hospitalization—after an HD predictive-testing result,
through questionnaires sent to predictive-testing centers
worldwide. A total of 44 persons (0.97%) in a cohort
of 4,527 test participants had a CE: 5 successful suicides,
21 suicide attempts, and 18 hospitalizations for psychi-
atric reasons. All persons committing suicide had signs
of HD, whereas 11 (52.4%) of 21 persons attempting
suicide and 8 (44.4%) of 18 who had a psychiatric hos-
pitalization were symptomatic. A total of 11 (84.6%)
of 13 asymptomatic persons who experienced a CE dur-
ing the first year after HD predictive testing received an
increased-risk result. Factors associated with an in-
creased risk of a CE included (a) a psychiatric history
5 years prior to testing and (b) unemployed status.
The frequency of CEs did not differ between those per-
sons receiving results of predictive testing through link-
age analysis in whom there was only changes in direction
of risk and those persons receiving definitive results after
analysis for the mutation underlying HD. These findings
provide insights into the frequency, associated factors,
and timing of CEs in a worldwide cohort of persons
receiving predictive-testing results and, as such, highlight
persons for whom ongoing support may be beneficial.
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Introduction
During the past decade, molecular genetics research has
led to the identification of an increasing number of dis-
ease-associated genes. Genetic testing is now available
to assess whether an at-risk individual has inherited the
DNA changes predictive of a clinical phenotype (pre-
dictive testing) and to confirm the diagnosis for symp-
tomatic individuals (Miki et al. 1994; Nicolaides et al.
1994; Wooster et al. 1995; Reddy and Housman 1997).
For Huntington disease (HD [MIM 143100]), an au-
tosomal dominant neurodegenerative disorder with late
onset, linkage analysis for predictive testing started in
1986, initially in Canada (Fox et al. 1989) and the
United States (Meissen et al. 1988; Brandt et al. 1989)
and then in many center around the world (World Fed-
eration of Neurology Research Group on Huntington’s
Disease 1993). Later, when the specific mutation asso-
ciated with HD was identified, direct testing for the mu-
tation became available (Huntington’s Disease Collab-
orative Research Group 1993).
For many years, prior to the implementation of test-
ing, serious concerns were raised as to whether it was
ethical to offer predictive testing for a disease for which
no treatment was available (National Institutes of
Health 1977; Marsden 1981). It was feared that the test
results could precipitate depression, anxiety, marital and
family stress, survivor’s guilt, and social stigmatization
and discrimination in employment and insurance (Kenen
and Schmidt 1978; Rosenfeld 1984; Wexler 1985). In
addition, there was concern that individuals who learn
that they will develop HD in the future may be at greater
risk for catastrophic outcomes such as suicide, attempted
suicide, or psychiatric hospitalization. This concern was
based on higher suicide rates reported for HD patients
compared with the general population (Hayden et al.
1980; Schoenfeld et al. 1984; Farrer 1986; Sørensen and
Fenger 1992; Di Maio et al. 1993) and higher rates of
psychiatric problems for persons at risk for HD (Oliver
1970; Kessler 1987). Furthermore, surveys of attitudes
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toward predictive testing indicated that 11%–15% of
at-risk individuals would contemplate suicide if they re-
ceived an increased-risk result (Kessler et al. 1987; Mas-
tromauro et al. 1987).
There have been a number of reports on the short-
term psychosocial impact that predictive testing for HD
has on individuals. The overall impression with regard
to many tested individuals, in both the decreased- and
the increased-risk groups, is that being informed of their
genetic status relative to the mutation for HD is bene-
ficial to them, although a significant proportion of in-
dividuals experience feelings of sadness, hopelessness,
and depression (Nance et al. 1991; Bloch et al. 1992;
Huggins et al. 1992; Tyler et al. 1992; Codori and Brandt
1994; Codori et al. 1997; Taylor and Myers 1997). Dif-
ficulties with coping with a new genetic status have also
been described in case reports (Bloch et al. 1992; Hug-
gins et al. 1992; Almqvist et al. 1997; Robins Wahlin
et al. 1997). However, as a group, both decreased- and
increased-risk individuals showed less psychological dis-
tress during the 1st year after testing, and this was par-
ticularly evident for those who either received a de-
creased-risk result or were informed that they had a
normal CAG repeat length (Brandt et al. 1989; Wiggins
et al. 1992; Decruyenaere et al. 1996; Tibben et al.
1997).
The frequency of adverse reactions (defined as suicidal
ideation, psychiatric hospitalization, depression, rela-
tionship breakdown, substance abuse, or psychological
distress) after the predictive-testing result was shown to
be ∼16% (15/95) among the tested individuals in a Ca-
nadian study, but no significant difference in frequency,
between the increased- and the decreased-risk groups,
was found (Lawson et al. 1996). Furthermore, Quaid
(1993) reported on 4 (2.1%) of 189 individuals in a U.S.
predictive-testing sample who were hospitalized after re-
ceiving the results (3 received an increased-risk result,
and 1 received a decreased-risk result). However, these
studies were in relatively small cohorts, and, until now,
no estimates of the frequency of CEs in a large cohort
of patients have been ascertained.
The goal of this survey was to determine the world-
wide frequency of CEs after predictive testing for HD
and to study factors that might influence its occurrence.
These factors might help to identify individuals at high-
est risk for CEs, toward whom strategies of support may
be directed, in order to prevent these serious adverse
reactions. These data may also prove useful for other
predictive-testing programs for late-onset hereditary
diseases.
Subjects and Methods
A total of 175 centers in 26 countries that have offered
predictive testing for HDwere identified through contact
with the International Huntington Association (a lay or-
ganization for HD) and professionals from participant
lists from the World Federation of Neurology Research
Group on HD. All centers were invited to participate in
the present survey by completing a questionnaire (ques-
tionnaire 1A) providing demographic data and test re-
sults on all participants who had received predictive-
testing results at their center. Diagnostic tests for symp-
tomatic participants suspected of having HD were not
included in the survey.
For those test candidates who had experienced a CE
after the predictive-testing result, an additional ques-
tionnaire (questionnaire 1B) was completed. A CE was
defined as (i) suicide, (ii) suicide attempt, or (iii) psy-
chiatric disorder requiring hospital admission. Infor-
mation concerning the CE—including when it occurred
relative to the time of receipt of the predictive-testing
results, clinical status at the time of the CE (in which
the status, as rated by the test center, was asymptomatic,
possibly affected, probably affected, or diagnosed HD),
and direction of predictive-testing results—was pro-
vided. Demographic data—including gender, age, mar-
ital status, and employment status—were documented.
A positive psychiatric history 5 years prior to predic-
tive testing was assigned if a suicide attempt, psychiatric
hospitalization, or treatment by medications for psy-
chological or psychiatric reasons had occurred. The pro-
tocol for the center’s predictive-testing programwas also
attached.
In addition, we inquired that all participating centers
provide information on the date of the predictive-testing
result and the last follow-up contact, either in person or
via letter or phone call, on all tested participants (ques-
tionnaire 1C). On the basis of these data, we estimated
the length of follow-up after the predictive-testing re-
sults, for all persons.
Ascertainment
The generalizability of such a study is influenced sig-
nificantly by the level of ascertainment. A potential
source of bias and underascertainment of CEs could re-
sult from centers that had a higher frequency of CEs but
that did not wish to participate in the survey. Therefore,
an additional short questionnaire (questionnaire 2) was
sent to centers that did not participate in this survey,
requesting the total number of predictive-testing results
provided at the center, as well as the number and type
of CEs that had occurred.
Statistical Analyses
A Student’s t-testing was used to assess differences in
mean age. Fisher’s exact test was used for 2#2 com-
parisons, and x2 analyses were used for other compar-
isons, to examine the differences, in demographic data,
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Table 1
Direction of Predictive-Testing Results and Frequency of CEs
TEST AND RESULT
NO. (%) OF PARTICIPANTS
PcWithout a CEa With a CEb
NO. (%) OF CEs IN
COHORT
Linkage analysis:
Increased risk 251 (34.3) 6 (66.7) Not significant 6/257 (2.3)
Decreased risk 451 (61.6) 3 (33.3) 3/454 (.7)
Uninformative result 30 (4.1) 0 (0) 0/ 30 (0)
Total 732 (100) 9 (100) 9/741 (1.2)
Direct test:
Mutation carrier 1,529 (40.8) 31 (88.6) !.0001 31/1,560 (2.0)
Normal CAG length 2,143 (57.1) 4 (11.4) 4/2,147 (.9)
Intermediate allele 79 (2.1) 0 (0) 0/ 79 (0)
Total 3,751 (100) 35 (100) 35/3,786 (.9)
Totals for both linkage analysis and direct testing:
Increased risk/mutation carrier 1,780 (39.7) 37 (84.1) !.0001 37/1,817 (2.0)
Decreased risk/normal CAG length 2,594 (57.9) 7 (15.9) 7/2,601 (.3)
Uninformative result by linkage analysis 30 (.7) 0 (0) 0/30 (0)
Intermediate allele 79 (1.8) 0 (0) 0/ 79 (0)
Grand total 4,483 (100) 44 (100) 44/4,527 (.97)
a Participants who underwent both linkage analysis and direct testing (235 [5.2%] of all those without CE) are included in the
direct-testing group.
b For the six participants with a CE who underwent both linkage analysis and direct testing, test results are reported with respect
to the test after which the CE occurred.
c Data are for comparisons between the participants with a CE and those without a CE, in the increased-risk group versus the
decreased-risk group.
between the group of participants with a CE and either
the group of participants without a CE or, when the
latter group was not available, a worldwide sample com-
prising pooled demographic data from published papers
on HD predictive-testing participants. Because of dif-
ferences in reported demographic data in these papers,
the total number of tested participants varies for each
demographic factor: (i) marital status includes data from
Simpson et al. (1992), Holloway et al. (1994), Codori
et al. (1997), Decruyenaere et al. (1997), Taylor and
Myers (1997), Tibben et al. (1997), and E. Almqvist,
M. Hayden, unpublished data; (ii) employment status
includes data from Codori et al. (1997), Decruyenaere
et al. (1997), Tibben et al. (1997), and E. Almqvist, M.
Hayden, unpublished data; and (iii) previous psychiatric
history includes data from Lawson et al. (1996) and E.
Almqvist, M. Hayden, unpublished data.
Results
A total of 100 centers in 21 countries from five con-
tinents participated in this study (see the Appendix).
These 100 centers reported that a total of 4,527 partic-
ipants had received a predictive-testing result—via either
linkage analysis ( [16.4%]), direct testing of then  741
CAG repeat in the HD gene ( [83.6%]), orn  3,786
both ( [5.3%]) (table 1)—and were followedn  241
after receiving the predictive-testing results. A total of
1,817 participants (40.1%) received either an increased-
risk result or an expanded CAG repeat 135; 2,601 par-
ticipants (57.5%) received either a decreased-risk result
or normal CAG length; 30 participants (0.7%) received
an uninformative result from linkage analysis; and 70
participants (1.5%) had an intermediate-sized allele (ta-
ble 1). The mean age at disclosure of the test result was
37.4 years, and the sample consisted of 40.7% males
and 59.3% females (table 2).
An additional 441 tested participants from these cen-
ters received the predictive-testing results but were not
included in this survey, because of the absence of follow-
up (441/4,968 participants [8.9%]). Of these 441, 119
(27%) received an increased-risk result, 313 (71%) re-
ceived a decreased-risk result, and 9 (2%) received either
an uninformative result or an intermediate allele.
CEs
Frequency.—Of the 4,527 participants, 44 (0.97%)
were reported to have experienced a CE after receiving
the predictive-testing results (table 1): 5 participants, all
women, committed suicide; 21 (13 women and 8 men)
attempted suicide, and 18 (13 women and 5 men) were
hospitalized for psychiatric reasons. All participants
with a CE, irrespective of its apparent relationship with
the predictive-testing result, were included.
Direction of the test result.—Of the 44 participants
who had experienced a CE, 37 (84.1%) either had re-
ceived an increased-risk result via linkage analysis
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Table 2
Predictive-Testing Participants, by Age and Sex
AGE
(years)
NO. (%) OF
Mena Womenb Totalc
Participants
with a CE
16–19 23 (1.2) 58 (2.2) 81 (1.8) 0 (0)
20–29 428 (23.2) 687 (25.6) 1,115 (24.6) 8 (18.2)
30–39 670 (36.4) 904 (33.7) 1,574 (34.8) 17 (38.6)
40–49 417 (22.7) 640 (23.8) 1,057 (23.3) 17 (38.6)
50–59 199 (10.8) 278 (10.3) 477 (10.5) 2 (4.5)
60–69 78 (4.2) 87 (3.2) 165 (3.6) 0 (0)
70–79 20 (1.1) 26 (1.0) 46 (1.0) 0 (0)
80–90 1 (.05) 4 (.1) 5 (.1) 0 (0)
Unknown 5 (.3) 2 (.07) 7 (.2) 0 (0)
Total 1,841 (100) 2,686 (100) 4,527 (100) 44 (100)
Total by sex 1,841 (40.7) 2,686 (59.3)
a Mean Age  SD  years.37.6 12.4
b Mean Age  SD  years.37.3 11.5
c Mean Age  SD  years.37.4 11.9
( ) or were HD mutation carriers ( ). Thisn  6 n  31
represented 37/1,817 (2%) of the cohort receiving in-
creased-risk results, which was significantly greater than
the frequency of CEs in those receiving decreased-risk
results (7/2,601 [0.3%]; [see table 1]). ThereP ! .0001
were two participants in this CE sample who received
a risk estimate, via linkage analysis, that was revised
from decreased risk to increased risk. The corrected risks
were used in the computation of the test-results data.
No significant difference in frequency of CEs was seen
between the linkage-analysis group (9/741 participants
[1.2%]) and the direct-testing group (35/3,786 partici-
pants [0.9%]) (table 1).
Clinical status.—A total of 24 (54.5%) of those who
experienced a CE were already symptomatic at the time
of the CE—that is, were either diagnosed ( ) orn  8
rated as probably ( ) or possibly ( ) affectedn  7 n  9
(tables 3 and 4). The eight affected persons experienced
their CEs at varying times (0–28 mo) after diagnosis
(table 5). In particular, all who committed suicide were
symptomatic (four were diagnosed, and one was prob-
ably affected) at the time of the CE. Of those with an
increased risk, 24 (64.8%) of 37 were symptomatic at
the time of the CE.
Timing of the CE.—The mean incidence of CEs was
0.44%/year (range 0.35%–0.65%/year) (table 3). No
significant variation in frequency of CEs over time was
seen relative to time of receipt of the predictive-testing
result. There was at least one follow-up contact with all
participants during the first 6 mo after testing, and
0.35% (16/4,527) experienced a CE during this period,
and three of these CEs occurred 1 mo after receipt of
the results. For subsequent follow-up periods, the fre-
quencies were as follows: 6–12 mo after testing, 0.37%
(10/2,679); 1–2 years after testing, 0.45% (9/1,992); 2–3
years after testing, 0.65% (or 7/1,074); and 3–4 years
after testing, 0.37% (2/540) (table 3 and fig. 1).
The majority (4/7 [57.1%]) of those who received a
decreased-risk result experienced the CE 11 year after
receiving the result, in contrast with the increased-risk
group, in which most (23/37 [62.1%]) participants ex-
perienced a CE during the 1st year. The numbers, how-
ever, are small in both of these groups.
The mean time interval for occurrence of the CE after
receipt of predictive-testing results was mo14.4 12.6
(range 0.5–42 mo) for symptomatic participants,
whereas it was mo (range 0.5–29 mo) for10.1 8.8
asymptomatic participants (not significant). The mean
time interval for those who committed suicide was
mo (range 3–35 mo); for those who at-18 12.9
tempted suicide, mo (range 0.5–29 mo); and,9 8.7
for those who were hospitalized, mo (range14.9 12.4
0.5–42 mo) (not significant).
Previous psychiatric history.—A total of 15 (38.5%)
of 39 participants with a CE had a psychiatric history
5 years prior to the predictive testing (for 5 partici-
pants, status was unknown), which is a significantly
greater frequency than that in the predictive-testing com-
parison group ( ; see table 4): 2 of these par-P ! .0005
ticipants had attempted suicide 5 years prior to en-
tering the predictive-testing program; 12 of these
participants were treated, by medication, for depression;
and 1 was hospitalized for other major psychiatric prob-
lems prior to predictive testing.
Other demographic characteristics.—The CE group
comprises participants from nine countries (Australia,
Belgium, Canada, France, Germany, the Netherlands,
Sweden, the United Kingdom, and the United States).
Age, gender, and marital status did not influence the
likelihood of a CE, compared with the likelihood ob-
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Table 3
Follow-up Period after Predictive-Testing Results, and Timing of CE
LENGTH OF
FOLLOW-UP
NO. (%) OF
PARTICIPANTS
NO. OF
PARTICIPANTS
WITH A CE
(% OF
TOTAL)
NO. OF PARTICIPANTS (% OF CE
GROUP) WHO ARE
Symptomatic
Asymptomatic
With
Increased
Risk
With
Decreased
Risk
.5–6 mo 4,527 (100) 16 (.35) 8 (50.0) 6 (37.5) 2 (12.5)
6–12 mo 2,679 (59.2) 10 (.37) 4 (40.0) 5 (50.0) 1 (10.0)
1–2 years 1,992 (44.0) 9 (.45) 6 (66.7) 2 (22.2) 1 (10.0)
2–3 years 1,074 (23.7) 7 (.65) 4 (57.1) 3 (42.9)
3–4 years 540 (11.9) 2 (.37) 2 (100)
4–5 years 375 (8.3)
5–6 years 245 (5.4)
6–7 years 130 (2.9)
7–8 years 70 (1.5)
8–9 years 23 (.5)
9–10 years 1 (.02)
10–11 years 1 (.02)
Total 44 (.97) 24 (54.5) 13 (29.5) 7 (15.9)
served in the combined worldwide predictive-testing
sample (table 4). In contrast, employment status was
significantly related to the frequency of CE, with 23
(52.3%) of 44 such persons being unemployed versus
43 (14.3%) of 300 in the combined predictive-testing
sample ( ; see table 4).P ! .0001
Ascertainment.—We received complete information
(questionnaires 1A, 1B, and C) from 100 (57.1%) of the
175 centers. In an effort to determine whether we might
have underascertained the frequency of CEs, and
whether centers with more CEs were less likely to com-
plete the questionnaires, we specifically inquired, of
those centers that did not provide complete information
(on either questionnaires 1A and 1B or questionnaire 2
only), as to the number of tested participants and CEs
in their center. We received information from 47 addi-
tional centers, providing an ascertainment of the fre-
quency of CEs from a total of 147 (84%) of the 175
centers. These additional 47 centers reported that 11
(0.4%) of 2,985 tested participants had experienced a
CE. This number was significantly lower ( ) thanP ! .004
that seen in the initial cohort, which suggested that un-
derascertainment of CEs in the centers that did not fill
out all the questionnaires was not likely to have under-
mined the scientific integrity and validity of this study.
Discussion
Bundey (1997, p. 4) recently has proclaimed that pre-
dictive “genetic testing for HD is a success story, and
the few adverse effects should be put into context of the
many thousands of individuals who have been relieved
of the anxiety of not knowing whether or not HDwould
develop.” Although the present survey of CEsworldwide
could be interpreted as supporting that view—in that,
over varying periods of follow-up, only 0.97% of all
tested participants experienced a catastrophic reaction
to predictive testing—this frequency is still high and, in
fact, represents a minimum frequency, despite attempts
to achieve as high an ascertainment rate as possible.
Furthermore, since the time of ascertainment varied
among patients, with 59% being followed up 1 year
after receiving results, longer-term follow-up would be
likely to reveal additional instances of CEs with respect
to predictive testing in this cohort.
Even though ascertainment was relatively high for this
study, with follow-up data collected from 84%of centers
participating in predictive testing, one potential concern
still remains—that is, that CEs may be higher in those
persons who had no follow-up. One way to address this
is to assess whether persons with no follow-up were
more likely to have received an increased-risk result. In
this group with no follow-up, 27% received an in-
creased-risk result, and 71% received a decreased-risk
result, compared with 40.1% and 57.5%, respectively
( ), in the group with follow-up, suggestingP ! .00001
that lack of follow-up in this small proportion of patients
is unlikely to have altered the findings of this study.
It is also important to note that the frequency of CEs
reported in the present study is based on reports from
established predictive-testing centers that essentially fol-
low protocols recommended by the World Federation of
Neurology, Research Committee, Research Group on
Huntington’s Chorea (1989). It is possible that those
centers not following such protocols would have an in-
creased frequency of serious side effects.
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Table 4
Demographics of Participants with a CE versus Those without a CE
NO. (%) OF PARTICIPANTS
Pf
With a CE
Without a CEe
Predictive-
Testing
Comparison
GroupSuicidea
Suicide
Attemptb
Psychiatric
Hospitalizationc Totald
Sex:
Female 5 13 13 31 (70.4) 2,656 (59.2) 321 (59.1) NSg
Male 0 8 5 13 (29.6) 1,827 (40.8) 222 (40.9)
Total 5 21 18 44 (100) 4,483 (100) 543 (100)
Predictive-testing results:
Increased risk/mutation 5 17 15 37 (84.1) 1,780 (39.7) Not available !.0001
Decreased risk/normal 0 4 3 7 (15.9) 2,594 (57.9)
Intermediate allele 0 0 0 0 (0) 79 (1.8)
Uninformative (linkage analysis) 0 0 0 0 (0) 30 (.7)
Total 5 21 18 44 (100) 4,483 (100)
Time (after receipt of results) when CE occurred:
0–6 mo 1 10 5 16 (36.4) Not applicable Not applicable
6–12 mo 1 5 4 10 (22.7)
1–2 years 1 3 5 9 (20.4)
2–3 years 2 3 2 7 (15.9)
3–4 years 0 0 2 2 (4.5)
4–5 years 0 0 0 0 (0)
5–6 years 0 0 0 0 (0)
6–7 years 0 0 0 0 (0)
Total 5 21 18 44 (100)
Clinical status when CE occurred:
Asymptomatic 0 10 10 20 (45.5) Not applicable Not applicable
Possibly affected 0 4 5 9 (20.4)
Probably affected 1 4 2 7 (15.9)
Diagnosed 4 3 1 8 (18.2)
Total 5 21 18 44 (100)
Marital status:
Married or common-law man and wife 2 11 12 25 (56.8) Not available 371 (68.3) NSh
Single or equivalent 3 10 6 19 (43.2) 172 (31.7)
Total 5 21 18 44 (100) 543 (100)
Employment status:
Employed 0 10 11 21 (47.7) Not available 257 (85.7) !.0001h
Unemployed 5 11 7 23 (52.3) 43 (14.3)
Total 5 21 18 44 (100) 300 (100)
Psychiatric history 5 years prior to predictive
testing:
Present 2 7 6 15 (38.5) Not available 15 (12.6) !.0005h
Absent 2 12 10 24 (61.5) 104 (87.4)
Total 4 19 16 39 (100)i 119 (100)
a Mean age  SD  years (range 21–47 years).36.6 10.1
b Mean age  SD  years (range 24–55 years).37.3 9.7
c Mean age  SD  years (range 27–47 years).36.7 6.4
d Mean age  SD  years (range 21–55 years).37.0 8.3
e Mean age  SD  years (range 16–90 years).37.4 11.9
f NS  not significant.
g Comparison of total no. of participants with a CE versus total no. of participants without a CE.
h Comparison of total no. of participants with a CE versus predictive-testing comparison group (pooled data; see Subjects and Methods).
i For five participants, psychiatric history was unknown.
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Figure 1 Proportion of participants, in the total group, who had
a CE, with regard to timing of CE after receipt of predictive-testing
results. Participants who were rated by the predictive-testing center as
diagnosed, probably affected, or possibly affected are included in the
category of “Symptomatic” participants.
Table 5
Timing of CE and HD Diagnosis after Predictive-Testing Result
PARTICIPANT TYPE OF CE
TIME, AFTER PREDICTIVE
TESTING RESULT, OF
(mo)
TIME, AFTER HD
DIAGNOSIS, OF CE
OCCURRENCE
(mo)CE Occurrence Diagnosisa
1 Suicide attempt 1 0 1
2 Suicide 3 3 0
3 Psychiatric hospitalization 3 1.5 1.5
4 Suicide 8 0 8
5 Suicide attempt 12 0 12
6 Suicide attempt 24 12 12
7 Suicide 25 0 25
8 Suicide 35 7 28
a 0  diagnosis at the same time that predictive-testing results were received.
Certain demographic features of this cohort are in-
teresting, particularly in view of the fact that it is the
largest cohort of predictive-testing subjects ever studied.
Worldwide, the mean age at predictive testing is 37 years
(range 16–90 years), again indicating that, worldwide,
predictive testing often is being undertaken after persons
have made reproductive decisions. In addition, as re-
ported elsewhere (Holloway et al. 1994; Lawson et al.
1996; Codori et al. 1997; Tibben et al. 1997), the ma-
jority (59%) of participants are female. In addition, there
was a trend toward an excess of female participants who
experienced a CE (70.4% [31/44] of women, vs. 29.6%
[13/44] of men; ).P  .18
Numerous issues with clinical implications emerged
from this study. Fully 54.5% of persons with a CE were
symptomatic at the time of the event, clearly highlighting
the vulnerability of this particular group of increased-
risk participants who begin manifesting with signs and
symptoms. Prior to the advent of predictive testing, the
time around the onset of HD has been recognized as a
time of high risk for suicide, since persons aware of the
course of the illness are still able to both plan and im-
plement a suicide strategy. Although predictive testing
cannot definitively be invoked as contributing to these
persons’ CEs, predictive testing in all likelihood played
a significant role in the CE of asymptomatic persons.
The majority (11/13 [84.6%]) of asymptomatic partic-
ipants who experienced a CE 12 mo after receiving
results, received an increased-risk result. By contrast, af-
ter 1 year the majority (4/7 [57.1%]) of CEs occurred
in persons who received a decreased-risk result. How-
ever, the longer the time after results, the more likely it
is that factors either other than or in addition to the
results contributed to the CE.
This study has helped to identify those factors that
might be associated with an increased frequency of su-
icide, suicide attempt, or psychiatric hospitalization after
predictive testing. Awareness of these risk factors may
be extremely important, since it allows for identification
of a subset of persons for whom increased counseling
and support may be helpful.
In this study, 38.5% of persons with a CE had a psy-
chiatric history 5 five years after entering the predic-
tive-testing program. In addition, more than half of those
with a CE, as well as all those who committed suicide,
were unemployed. Unemployment has previously been
shown to be a significant risk factor for suicide, but,
clearly, those participants who are most seriously de-
pressed are likely to be unemployed at that time (Platt
1984).
Clinical status was also an important predictor of a
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CE in this study; for example, 54.5% of all persons who
had a CE were possibly, probably, or recently diagnosed
with HD. Indeed, four of the five persons who com-
mitted suicide had recently been diagnosed with this ill-
ness. This provides further evidence that the risk of su-
icide is elevated during the period immediately after the
delivery of a diagnosis of HD.Of the 21 suicide attempts,
11 were by persons who also were symptomatic at the
time (table 4). Similarly, the risk for suicide attempts is
increased at the time of onset of the disease. Individual
case reports of the vulnerability of these patients have
been presented elsewhere (Bloch et al. 1993). Taken to-
gether, 54.5% of all CEs in this cohort occurred in per-
sons with some signs and symptoms of the illness.
The majority (37/44 [84.1%]) of the CE participants
who experienced a CE had received a predictive-testing
result indicating an increased risk of development of HD
in the future. Approximately 2% of all persons with an
increased-risk result had a CE, which was significantly
higher than the frequency of in the decreased-risk group
( ; see table 1). What is notable, however, isP ! .0001
that ∼0.3% (7/2,601) of participants in this sample who
either received a decreased-risk result or were informed
that the they had a normal CAG length in the HD gene
also had a CE, comprising four suicide attempts and
three psychiatric hospitalizations.
Although we and others (Nance et al. 1991; Bloch et
al. 1992; Huggins et al. 1992; Tyler et al. 1992; Codori
and Brandt 1994; Codori et al. 1997; Taylor and Myers
1997) have reported that adverse events may occur in
both the increased- and decreased-risk groups, this is the
first report of a CE in persons ( ) who have beenn  7
told that they will not develop HD. These seven persons
had other factors that may have contributed to their risk
for a CE. Three of these seven participants had a pre-
vious psychiatric history; these included psychiatric
problems during adolescence, and, in one instance, the
participant became depressed and developed significant
ballistic movements and was diagnosed as HD, despite
the decreased-risk result. Direct testing was performed,
which confirmed the normal CAG length. However, this
was followed by a suicide attempt by this participant.
Another question that has been raised previously
(Mattsson and Winnberg Almqvist 1991; Babul et al.
1993) concerns the possibility that persons who have
received a direct-testing result may do less well than
persons who have received linkage-analysis results, since
in the latter of case the results would, because of the
possibility of recombination between the marker and the
gene, be less definitive. It has been suggested that the
possibility that this result could be incorrect might have
offered some hope to persons receiving an increased-risk
result. The role that this uncertainty played in main-
taining hope in these participants has not been previ-
ously assessed. The results of this study clearly show
that CEs occurred with equal frequency in participants
after linkage analysis and in those who received a de-
finitive result with regard to the presence or absence of
the mutation for HD. This suggests that the uncertainty
conferred by linkage analysis did not offer any added
comfort for at-risk participants previously participating
in predictive testing. Furthermore, direct assessmentwith
regard to the mutation did not eliminate hope for the
future and did not result in a significant increase in the
frequency of CEs in the population receiving definitive
results concerning future risk.
One pitfall of this study is the absence of a direct
comparison group of untested at-risk persons who have
been followed over time and have not participated in
predictive testing. Therefore, the relative estimated fre-
quency of CEs in the present study cannot be fully ap-
preciated until the occurrence of suicidal behavior or
psychiatric hospitalization among either nonparticipants
at risk or a comparable general population is known.
Prior estimates of suicide frequency in families with HD
with rates have been four to eight times that seen in the
corresponding general population in which the study
was undertaken (Schoenfeld et al. 1984; Farrer 1986;
Sørensen and Fenger 1992; Di Maio et al. 1993). Suicide
attempts were seen in ∼25% of all HD patients assessed
(Farrer 1986). These studies focused primarily on af-
fected patients, but the few studies of at-risk persons
also indicated rates that were at least two times greater
than those seen in the general population (Sørensen and
Fenger 1992; Di Maio et al. 1993). It is noteworthy that,
worldwide, there were no instances of suicide in men in
the predictive-testing program but that there were five
suicides in women. Although the suicide rate of the pre-
dictive-testing population is lower for men and higher
for women than what is seen in similar-age cohorts in
the Canadian general population (Health Canada 1994,
p. 36–42), both the absence of a comparable control
group and the size of the cohorts in the present study
limit the usefulness of such comparisons. Whether this
reflects a true lower rate of CEs among males than might
be expected for persons at risk for HD or, rather, is an
indication of self-selection of persons in predictive-test-
ing programs who may be psychologically better
equipped with good coping skills is unknown (Codori
et al. 1994; Decruyenaere et al. 1995).
It is of interest that the frequency of CEs in the cohort
as a whole is constant over time. This suggests that other
factors, independent of the predictive-testing result, con-
tinue to make a significant contribution to the likelihood
of a CE in families with HD (fig. 1).
Overall, these results indicate that predictive testing
for HD may have serious risks, even though the fre-
quency of CEs may be lower than previously feared.
These findings emphasize both the importance of long-
term availability of support for persons receiving either
Almqvist et al.: Catastrophic Events after HD Gene Tests 1301
an increased- or decreased-risk result and the times at
which each of these groups may be most vulnera-
ble—that is, the presence of increased risk 1 year after
receipt of results and when the participants begin to
manifest with signs and symptoms. In contrast, persons
receiving a decreased-risk result are at low risk for hav-
ing a CE close to the time of receipt of results, but they
probably return to their baseline risk after the impact
of this information have been incorporated into their
lives and other factors are more prominent in influencing
psychological well-being. The study also highlights fea-
tures in the clinical history that may serve to alert the
clinician to the need for the most vigilant ongoing psy-
chological support.
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Appendix
Participating Centers with Follow-up Data (no. of in-
dividuals tested)
Australia ( ):n  646
J. Conaghan, Hunter Genetics, Waratah, New
South Wales
C. Hempel, Flinders Medical Centre, Bedford Park,
South Australia
T. Liebeck and C. Connor, Selby Centre, Shenton
Park, Western Australia
F. Richards, The New Children’s Hospital, Parra-
matta, New South Wales
I. Simpson and Dr. A. Waugh, Aspley Community
Health Services, Queensland
S. Taylor, Launceton General Hospital, Launceston,
Tasmania
Austria ( ):n  9
Dr. H. Aschauer, University Hospital Psychiatry,
Vienna
Belgium ( ):n  190
Drs. A. De Paepe and A. Van Tongerloo, Univer-
sitair Ziekenhuis, Gent
Dr. G. Evers-Kiebooms, UniversitaireZiekenhuizen,
Leuven
Dr. C. Verellen, Universite Catholique de Louvain,
Brussels
Dr. A. Verloes, Centre Hopital Universitaire, Liege
Canada ( ):n  641
Drs. E. Almqvist, M. Bloch, and M. Hayden, UBC
Hospital, Vancouver
Dr. S. Bamforth, University of Alberta’s Hospital,
Edmonton
S. Cardwell, Royal University Hospital, Saskatoon
M. Crowley and Dr. E. Ives, Janeway Child Health
Centre, St. John’s, Newfoundland
S. Dufrasne, McGill University, Montreal
D. Eisenberg and Dr. D. Whelan, McMaster Uni-
versity Medical Centre, Hamilton, Ontario
A. Fuller, IWK Grace Health Centre, Halifax, Nova
Scotia
C. Gillies, Thunder Bay District Health Unit, Thun-
der Bay, Ontario
Dr. C. Greenberg, Children’s Hospital, Winnipeg
H. Hare, Sudbury & District Health Unit, Sudbury,
Ontario
M. Johnstone, Oshawa General Hospital, Oshawa,
Ontario
R. Lokkesmoe, Queen’s University, Kingston,
Ontario
Dr. P. MacLeod, Victoria General Hospital, Victo-
ria, British Columbia
C. Prevost, Hoˆpital de Chicoutimi, Chicoutimi,
Quebec
F. Robert, North Bay District Health Unit, North
Bay, Ontario
Czech Republic ( ):n  1
Dr. J. Zidovska, Teaching Hospital of Charles Uni-
versity, Prague
Finland ( ):n  13
Dr. M. Peippo, The Family Federation of Finland,
Helsinki
France ( ):n  178
Dr. A. Durr, Hopital de la Salpetriere, Paris
Dr.M.-C.Malinge, Centre R. Debre CHUd’Angers,
Angers
Dr. H. Pison, Service de Cytogenetique, Grenoble
Drs. H. Plauchu, E. Ollagnon, and T. d’Amato,
Hoˆpital Hoˆtel Dieu, Lyon
Drs. F. Tison and D. Lacombe, Hopital Pellegrin,
Bordeaux
Dr. J. Yaouanq, Hopital Pontchaillou, Rennes
Germany ( ):n  124
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Drs. J. Epplen, A. Riess, and O. Riess, Ruhr-Univ-
ersita¨t, Bochum
Drs. D. Nolte and U. Mueller, Institute of Human
Genetics, Giessen
Drs. Schwinger and U. Zu¨hlke, Institut fu¨r Hu-
mangenetik, Universita¨t Lu¨beck, Lu¨beck
Israel ( ):n  16
Dr. M. Frydman, Sheba Medical Centre, Tel
Hashomer
Italy ( ):n  53
Dr. G. Campanella, University Federico II, Naples
Drs. M. Frontali and A. Jacopini, Istituto Medicina
Sperimentale CNR, Rome
Mexico ( ):n  12
Dr. E. Alonso Vilatela, Instituto Nacional de Neu-
rologia y Neurocirugia, Col. La Fama
The Netherlands ( ):n  566
Dr. J. Cobben, Gro¨ningen University, Gro¨ningen
N. Knoers, University Hospital, Nijmegen
Drs. A. Maat-Kievit and M. Vegter-van der Vlis,
Academisch Ziekenhuis, Leiden
Dr. R. Richard, Academic Medical Centre,
Amsterdam
Dr. A. Tibben, Erasmus University, Rotterdam
New Zealand ( ):n  110
Dr. W. Cambourn, Wellington Hospital, Wellington
Dr. A. Macleod, Psychiatric Consult. Services,
Christchurch Hospital, Christchurch
Dr. I. Winship, J. Giles, Northern Regional Genetic
Services, Auckland
South Africa ( ):n  55
Dr. J. Greenberg, UCT Medical School, Cape Town
Drs. A. Krause, J. Kromberg, University of Wit-
watersrand, Johannesburg
Dr. M. Marx, University of Stellenbosch, Tygerberg
Dr. W. Winship, University of Natal Genetic Clinic,
Durban
Spain ( ):n  45
Dr. J. Garcia de Yebenes, Universidad Autonoma
de Madrid, Madrid
Dr. M. Ramos-Arroyo, Hospital Virgen del Cam-
ino, Pamplona
Sweden ( ):n  55
A. Haegermark, Drs. M. Anvret and A. Lundin,
Karolinska Hospital, Stockholm
Dr. U. Kristoffersson, University Hospital, Lund
United Kingdom: U.K. Huntington’s Prediction Con-
sortium ( ):n  1,017
C. Benjamin and Dr. A. Fryer, Royal Liverpool Chil-
dren’s Hospital, Liverpool
Dr. D. Craufurd, St. Mary’s Hospital, Manchester
R. Glew and Dr. S. Huson, Oxford Radcliffe Hos-
pital Trust, Oxford
J. Haydon and Dr. S. Bundey, BirminghamWomen’s
Hospital, Birmingham
Dr. S. Holloway, Western General Hospital,
Edinburgh
A. Howick and Dr. M. Patton, St. George’s Hos-
pital, London
A. Kershaw and Dr. J. Yates, Cambridge University,
Cambridge
A. Lashwood, Guy’s Hospital, London
E. McGhee, Dr. S. Raeburn, City Hospital,
Nottingham
Dr. P. Morrison, Northern IrelandGenetics Services,
Belfast
C. Patch and Dr. N. Dennis, The Princess Anne
Hospital, Southampton
B. Smith, D. Guthrie Institute of Medical Genetics,
Glasgow
Dr. R. Trembath, Leicester Royal Infirmary,
Leicester
Dr. G. Turner, St. James’s University Hospital, Leeds
G. Garner and Dr. P. Turnpenny, Royal Devon &
Exeter Hospital, Exeter
United States ( ):n  796
P. Allinson, University of Virginia Medical Center,
Charlottesville
Dr. H. Bass, Kaiser Permanente Medical Group,
Panorama City, CA
B. Baty, University of Utah Health Sciences Center,
Salt Lake City
R. Bennett and Dr. T. Bird, University of Washing-
ton Medical Center, Seattle
G. Brookshire, Children’s Medical Center, Dallas
M. Earnhart, Marshfield Clinic, Marshfield, WI
C. Evers, University of Iowa, Iowa City
L. Godmilow, University of Pennsylvania,
Philadelphia
D. Goodwin, Thomas Jefferson University,
Philadelphia
C. Gray, University of Kansas Medical Center, Kan-
sas City
C. Haverkamp, Kaiser Permanente, Denver
V. Hannig, Vanderbilt University Medical School,
Nashville
Dr. J. Johnson, Shodair Hospital, Helena, MT
Dr. R. Jones, Emory University School of Medicine,
Atlanta
K. Kovak, Oregon Health Sciences University,
Portland
K. Leonard, Baylor College of Medicine, Houston
C. Ludowese, Hennepin County Medical Center,
Minneapolis
Dr. G. Mengden, Southwest Genetics, San Antonio
Dr. T. Mueller, University of South Florida, Tampa
Dr. K. Quaid, Indiana University, Indianapolis
E. Otto, University of Missouri Hospital and Clin-
ics, Columbia
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N. Potter, University of Tennessee Medical Center,
Knoxville
Dr. F. Schaefer, Chapman Institute, Tulsa
Dr. C. Schramke, Veterans Affairs Medical Center,
Pittsburgh
Dr. K. Shannon, Rush-Presbyterian/St. Luke’s Med-
ical Center, Chicago
G. Suter, Donald J. Allen Memorial HD Clinic,
Wichita
Dr. D. Yim, Kaiser Permanente Medical Group,
Honolulu
A. Zanko, University of California Medical Center,
San Francisco
Electronic-Database Information
The accession number and URL for data in this article are
as follows:
Online Mendelian Inheritance in Man (OMIM), http://
www.ncbi.nlm.nih.gov/Omim (for HD [MIM 143100])
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